Skin Cancer Prevention (PDQ®): Prevention - Health Professional Information [NCI] - Description of the Evidence
BackgroundIncidence and mortalityThere are three main types of skin cancer:Basal cell carcinoma (BCC).Squamous cell carcinoma (SCC), which together with BCC is referred to as nonmelanoma skin cancer (NMSC).Melanoma.BCC and SCC are the most common forms of skin cancer but have substantially better prognoses than the less common, generally more aggressive, melanoma.NMSC is the most commonly occurring cancer in the United States. Its incidence appears to be increasing in some, but not all, areas of the country. Overall U.S. incidence rates have likely been increasing for a number of years. At least some of this increase may be attributable to increasing skin cancer awareness and resulting increasing investigation and biopsy of skin lesions. The total number and incidence rate of NMSCs cannot be estimated precisely because reporting to cancer registries is not required. However, based on extrapolation of Medicare fee-for-service data to the U.S.
Melanoma Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Treatment Option Overview
Melanomas that have not spread beyond the site at which they developed are highly curable. Most of these are thin lesions that have not invaded beyond the papillary dermis (Clark level I–II; Breslow thickness ≤1 mm). The treatment of localized melanoma is surgical excision with margins proportional to the microstage of the primary lesion; for most lesions 2 mm or less in thickness, this means 1 cm radial re-excision margins.[1,2]Melanomas with a Breslow thickness of 2 mm or more are still curable in a significant proportion of patients, but the risk of lymph node and/or systemic metastasis increases with increasing thickness of the primary lesion. The local treatment for these melanomas is surgical excision with margins based on Breslow thickness and anatomic location. For most melanomas more than 2 mm to 4 mm in thickness, this means 2 cm to 3 cm radial excision margins. These patients should also be considered for sentinel lymph node biopsy followed by complete lymph node
Skin Cancer Prevention (PDQ®): Prevention - Health Professional Information [NCI] - Interventions With Inadequate Evidence as to Whether They Reduce Risk of Nonmelanoma Skin Cancer
Sunscreen Use and Ultraviolet (UV) Radiation AvoidanceBenefitsThe evidence that interventions designed to reduce exposure to UV radiation by the use of sunscreen, protective clothing, or limitation of sun exposure time decrease the incidence of nonmelanoma skin cancer is inadequate. A randomized study suggested a possible reduction in incidence of squamous cell carcinomas (SCCs), but study design and analysis problems complicate interpretation of the results.[1,2]Magnitude of Benefit: Not applicable (N/A) (inadequate evidence).Study Design: One randomized controlled trial (RCT) with tumor incidence as the outcome and one RCT with actinic keratosis as the outcome for SCC; cohort studies for basal cell carcinoma (BCC). Other study designs give inconsistent results.Internal Validity: Poor.Consistency: Poor.External Validity: Poor.HarmsThe harms of sunscreen use are poorly quantified but are likely to be small, including allergic reactions to skin creams and lower production of vitamin D
Skin Cancer Prevention (PDQ®): Prevention - Health Professional Information [NCI] - Changes to This Summary (07 / 25 / 2013)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.Description of the EvidenceAdded text to state that the current evidence indicates that sunscreen application as practiced in the general population shows no clear association with reduced risk of melanocytic nevi or melanoma.This summary is written and maintained by the PDQ Screening and Prevention Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.
Intraocular (Uveal) Melanoma Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Extraocular Extension and Metastatic Intraocular Melanoma
Extrascleral extension confers a poor prognosis. For patients with gross tumor involvement of the orbit, treatment requires orbital exenteration. However, there is no evidence that such radical surgery will prolong life. Most patients with localized or encapsulated extraocular extension are not exenterated. This subject is controversial.[1,2,3,4,5]No effective method of systemic treatment has been identified for patients with metastatic ocular melanoma. Available clinical trials should be considered as an option for these patients.Current Clinical TrialsCheck for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with extraocular extension melanoma and metastatic intraocular melanoma. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.General information about clinical trials is also available from the NCI Web site.References: Shammas HF, Blodi FC: Prognostic factors in choroidal and
Intraocular (Uveal) Melanoma Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Changes to This Summary (11 / 09 / 2012)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.This summary was comprehensively reviewed and extensively revised.This summary is written and maintained by the PDQ Adult Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.
Intraocular (Uveal) Melanoma Treatment (PDQ®): Treatment - Patient Information [NCI] - Get More Information From NCI
Call 1-800-4-CANCERFor more information, U.S. residents may call the National Cancer Institute's (NCI's) Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237) Monday through Friday from 8:00 a.m. to 8:00 p.m., Eastern Time. A trained Cancer Information Specialist is available to answer your questions.Chat online The NCI's LiveHelp® online chat service provides Internet users with the ability to chat online with an Information Specialist. The service is available from 8:00 a.m. to 11:00 p.m. Eastern time, Monday through Friday. Information Specialists can help Internet users find information on NCI Web sites and answer questions about cancer. Write to usFor more information from the NCI, please write to this address:NCI Public Inquiries Office9609 Medical Center Dr. Room 2E532 MSC 9760Bethesda, MD 20892-9760Search the NCI Web siteThe NCI Web site provides online access to information on cancer, clinical trials, and other Web sites and organizations that offer support
Skin Cancer Screening (PDQ®): Screening - Patient Information [NCI] - What is screening?
Screening is looking for cancer before a person has any symptoms. This can help find cancer at an early stage. When abnormal tissue or cancer is found early,it may be easier to treat. By the time symptoms appear,cancer may have begun to spread. Scientists are trying to better understand which people are more likely to get certain types of cancer. They also study the things we do and the ...
Skin Cancer Screening (PDQ®): Screening - Patient Information [NCI] - nci_ncicdr0000258037-nci-header
This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at http://cancer.gov or call 1-800-4-CANCER.Skin Cancer Screening
Melanoma Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Cellular and Molecular Classification of Melanoma
Following is a list of clinicopathologic cellular subtypes of malignant melanoma. These should be considered descriptive terms of historic interest only as they do not have independent prognostic or therapeutic significance. Superficial spreading.Nodular.Lentigo maligna.Acral lentiginous (palmar/plantar and subungual).Miscellaneous unusual types: Mucosal lentiginous (oral and genital).Desmoplastic.Verrucous. Identification of activating mutations in the mitogen-activated protein kinase pathway has led to the definition of molecular subtypes of melanoma and provided potential drug targets.BRAF (V-raf murine sarcoma viral oncogene homolog B1) gene, first reported in 2002, are the most frequent mutation in cutaneous melanoma. Approximately 40% to 60% of malignant melanomas harbor a single nucleotide transversion. The majority have a mutation that results in a substitution from valine to glutamic acid at position 600 BRAF (V600E); less frequent mutations include valine 600 to lysine or